-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VGsZTMlDk7ZwkrSeAp1z0WcHBVZQ5XdCazGqvKOM7AAh5TuUfpXqiuyFTs8e0wCd T9h346fr6gAd+oSiwgoEsQ== 0000898437-98-000013.txt : 19981106 0000898437-98-000013.hdr.sgml : 19981106 ACCESSION NUMBER: 0000898437-98-000013 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19981105 EFFECTIVENESS DATE: 19981105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANIKA THERAPEUTICS INC CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043145961 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: SEC FILE NUMBER: 333-66831 FILM NUMBER: 98738520 BUSINESS ADDRESS: STREET 1: 236 WEST CUMMINGS PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 6179326616 MAIL ADDRESS: STREET 1: 236 WEST CUMMINGS PARK CITY: WOBURN STATE: MA ZIP: 01801 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 S-8 1 As filed with the Securities and Exchange Commission on November 5, 1998 Registration Statement No. 333- - ------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _________________________ Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Massachusetts 04-3145961 - ------------------------ --------------------------------------- (State of Incorporation) (I.R.S. Employer Identification Number) 236 West Cummings Park Woburn, Massachusetts 01801 ------------------------------------------------------------- (Address, including zip code, of Principal Executive Offices) Anika Therapeutics, Inc. 1993 Stock Option Plan ----------------------------------------------- (Full Title of the Plan) J. MELVILLE ENGLE President and Chief Executive Officer Anika Therapeutics, Inc. 236 West Cummings Park Woburn, Massachusetts 01801 (781) 932-6616 (Name, Address, and Telephone Number, Including Area Code, of Agent For Service) ____________________________ With copies to: H. DAVID HENKEN, ESQ. GOODWIN, PROCTER & HOAR LLP Exchange Place Boston, Massachusetts 02109-2881 (617) 570-1000 ------------------------------ CALCULATION OF REGISTRATION FEE
- ---------------------------------------------------------------------------- Proposed Proposed Title of Maximum Maximum Amount Securities Amount Offering Aggregate of to be to be Price Per Offering Registration Registered Registered (1) Share Price Fee - ---------------------------------------------------------------------------- Common Stock, par value $.01 per share 1,000,000 $5.438(2) $5,438,000 $1,511.76 - ---------------------------------------------------------------------------- (1) Plus such additional number of shares as may be required pursuant to the Registrant's 1993 Stock Option Plan in the event of a stock dividend, reverse stock split, split-up, recapitalization or other similar event. (2) This estimate is based on the average of the high and low sales prices of the common stock of Anika Therapeutics, Inc., par value $.01 per share, as reported on the Nasdaq National Market on October 30, 1998, pursuant to Rule 457(c) and (h) under the Securities Act of 1933, as amended (the "Securities Act"), solely for purposes of determining the registration fee.
PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT Item 3. Incorporation of Documents by Reference. Anika Therapeutics, Inc. (the "Registrant") hereby incorporates by reference the documents listed in (a) through (c) below, which have previously been filed with the Securities and Exchange Commission (the "Commission"): (a) The Registrant's Annual Report on Form 10-KSB for the fiscal year ended December 31, 1997; (b) All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") after December 31, 1997; and (c) The description of the Registrant's common stock contained in the Registrant's Registration Statement on Form 10, filed on March 5, 1993 and updated by the Registrant's Registration Statement on Form SB-2, as amended, filed on October 29, 1997. In addition, all documents subsequently filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents. Item 4. Description of Securities. Not applicable. Item 5. Interests of Named Experts and Counsel. The legality of the Common Stock offered hereby will be passed upon for the Registrant by Goodwin, Procter & Hoar LLP. As of the date of this Registration Statement, a total of 19,490 shares of Common Stock were beneficially owned by partner of Goodwin, Procter & Hoar LLP. Item 6. Indemnification of Directors and Officers. The Company is a Massachusetts corporation. Chapter 156B, Section 13 of the Massachusetts Business Corporation Law (the "MBCL"), enables a corporation in its original articles of organization or an amendment thereto to eliminate or limit the personal liability of a director for monetary damages for violations of the director's fiduciary duty, except (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Sections 61 and 62 of the MBCL (providing for liability of directors for authorizing illegal distributions and for making loans to directors, officers and certain shareholders), or (iv) for any transaction from which a director derived an improper personal benefit. Chapter 156B, Section 67 of the MBCL, provides that a corporation may indemnify directors, officers, employees and other agents and persons who serve at its request as directors, officers, employees or other agents of another organization or who serve at its request in any capacity with respect to any employee benefit plan, to the extent specified or authorized by the articles of organization, a by-law adopted by the stockholders or a vote adopted by the holders of a majority of the shares of stock entitled to vote on the election of directors. Such indemnification may include payment by the corporation of expenses incurred in defending a civil or criminal action or proceeding in advance of the final disposition of such action or proceeding, upon receipt of an undertaking by the person indemnified to repay such payment if he shall be adjudicated to be not entitled to indemnification under Section 67 which undertaking may be accepted with reference to the financial ability of such person to make repayment. Any such indemnification may be provided although the person to be indemnified is no longer an officer, director, employee or agent of the corporation or of such other organization or no longer serves with respect to any such employee benefit plan. No indemnification shall be provided, however, for any person with respect to any matter as to which he shall have been adjudicated in any proceeding not to have acted in good faith in the reasonable belief that his action was in the best interest of the corporation or to the extent that such matter relates to service with respect to any employee benefit plan, in the best interests of the participants or beneficiaries of such employee benefit plan. Article 6A of the Registrant's Restated Articles of Organization, as amended (the "Articles of Organization"), provides that except to the extent that Chapter 156B of the Massachusetts General Laws prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Registrant shall be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability. Article 6B of the Articles of Organization, provides that the Registrant shall indemnify each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was, or has agreed to become, a director or officer of the Registrant, or in any capacity with respect to any employee benefit plan of the Registrant (an "Indemnitee") against amounts paid and expenses incurred in connection with an action, suit or proceeding and any appeal therefrom, or settlement thereof, unless the Indemnitee shall be finally adjudicated not to have acted in good faith in the reasonable belief that his action was in the best interest of the Registrant (or participants or beneficiaries of any employee benefit plan of the Registrant). The Registrant shall not indemnify an Indemnitee seeking indemnification in connection with a proceeding initiated by the Indemnitee unless the initiation thereof was approved by the Board of Directors of the Registrant. Article 6B permits the payment by the Registrant of expenses incurred in defending any action, suit, proceeding or investigation in advance of its final disposition, if the Registrant does not assume the defense of Indemnitee, subject to receipt of an undertaking by the Indemnitee to repay such payment if it is ultimately determined that such Indemnitee is not entitled to indemnification under the Articles of Organization. Article 6B further permits that no indemnification or advancement of expenses may be made if such Indemnitee did not act in good faith in the reasonable belief that his action was in the best interest of the Registrant. Such determination shall be made in each instance by (a) a majority vote of a quorum of the directors of the Registrant, (b) a majority vote of a quorum of the outstanding shares of stock of all classes entitled to vote for directors, voting as a single class, which quorum shall consist of stockholders who are not at that time parties to the action, suit or proceeding in question, (c) independent legal counsel (who may be regular legal counsel to the Registrant), or (d) a court of competent jurisdiction. The Registrant has directors and officers liability insurance for the benefit of its directors and officers. Item 7. Exemption From Registration Claimed. Not applicable. Item 8. Exhibits. The following is a complete list of exhibits filed or incorporated by reference as part of this registration statement:
5.1 Opinion of Goodwin, Procter & Hoar LLP as to the legality of the securities being registered. 23.1 Consent of Goodwin, Procter & Hoar LLP (included in their opinion filed as Exhibit 5.1 hereto). 23.2 Consent of KPMG Peat Marwick LLP. 24.1 Power of Attorney (included on the signature page of this registration statement).
Item 9. Undertakings. (a) The Registrant hereby undertakes: (1) To file, during any period in which the Registrant offers or sells securities, a post-effective amendment to this Registration Statement: (i) To include any prospectus required by Section 10(a)(3) of the Securities Act; (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof), which individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in "Calculation of Registration Fee" table in the effective Registration Statement; (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; (2) That, for the purpose of determining any liability under the Securities Act, treat each such post-effective amendment as a new registration statement of the securities offered, and the offering of such securities at that time shall be deemed to be the initial bona fide; and (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. (b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woburn, Massachusetts on this 4th day of November 1998. Anika Therapeutics, Inc. By:/s/ J. Melville Engle --------------------- J. Melville Engle, President (Principal Executive Officer) and Director POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that we, the undersigned officers and directors of Anika Therapeutics, Inc. hereby severally constitute J. Melville Engle and Sean F. Moran, and each of them individually, our true and lawful attorneys with full power to them, to sign for us and in our names in the capacities indicated below, the Registration Statement filed herewith and any and all amendments to said Registration Statement, and generally do all such things in our names and in our capacities as officers and directors to enable Anika Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, and all requirements of the Securities and Exchange Commission, hereby ratifying and conforming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and any and all amendments thereto. Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
SIGNATURE CAPACITY DATE - -------------------- --------------------- ---------------- /s/ David A. Swann Chairman of the Board November 5, 1998 - -------------------- of Directors David A. Swann /s/ Joseph L. Bower Director November 5, 1998 - ------------------- Joseph L. Bower /s/ Eugene A. Davidson Director November 5, 1998 - ---------------------- Eugene A. Davidson /s/ Jonathan D. Donaldson Director November 5, 1998 - ------------------------- Jonathan D. Donaldson /s/ Samuel McKay Director November 5, 1998 - ------------------------- Samuel McKay /s/ Harvey Sadow Director November 5, 1998 - ------------------------- Harvey Sadow /s/ Steven E. Wheeler Director November 5, 1998 - --------------------- Steven E. Wheeler /s/ J. Melville Engle President (Principle November 5, 1998 - --------------------- Executive Officer) and J. Melville Engle Director /s/ Sean F. Moran Vice President of Finance November 5, 1998 - ----------------- and Treasurer (Principal Sean F. Moran Financial and Accounting Officer)
EXHIBIT INDEX
Exhibit No. Description Page - ----------- ----------------------------------------------- ---- 5.1 Opinion of Goodwin, Procter & Hoar LLP as to the legality of the securities being registered. 4 23.1 Consent of Goodwin, Procter & Hoar LLP (included in their opinion filed as Exhibit 5.1 hereto). 4 23.2 Consent of KPMG Peat Marwick LLP. 5 24.1 Power of Attorney (included on the signature page of this registration statement). 3 27.1 Financial Data Schedule
EXHIBIT 5.1 November 5, 1998 Anika Therapeutics, Inc. 236 West Cummings Park Woburn, MA 01801 Ladies and Gentlemen: This opinion is delivered in our capacity as counsel to Anika Therapeutics, Inc. (the "Company") in connection with the preparation and filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended, of a Registration Statement on Form S-8 (the "Registration Statement") relating to the issuance of shares of 1,000,000 shares of common stock, par value $.01 per share, of the Company (the "Shares"), issuable under the Company's 1993 Stock Option Plan. As counsel for the Company, we have examined the Company's Amended and Restated Articles of Organization and By-laws, each as presently in effect, and such records, certificates and other documents of the Company as we have deemed necessary or appropriate for the purposes of this opinion. We have also relied upon representations from the Company as to certain factual matters relevant to this opinion. Based on the foregoing, we are of the opinion that the Shares are duly authorized by the Company, and such Shares when issued and paid for in accordance with the terms of the Plan will be legally issued, fully paid and non-assessable. We hereby consent to being named as counsel to the Company in the Registration Statement and to the inclusion of this opinion as an exhibit to the Registration Statement. Very truly yours, GOODWIN, PROCTER & HOAR LLP EXHIBIT 23.2 CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS We consent to incorporation by reference in the registration statement (No. 333-xxxx) on Form S-8 of Anika Therapeutics, Inc. of our report dated February 18, 1998, relating to the balance sheets of Anika Therapeutics, Inc. as of December 31, 1997 and 1996, and the related statements of operations, stockholders' equity, and cash flows for the year ended December 31, 1997, the four month transitional year ended December 31, 1996 and the year ended August 31, 1996, which report appears in the December 31, 1997 annual report on Form 10-KSB of Anika Therapeutics, Inc. KPMG PEAT MARWICK LLP Boston, Massachusetts November 4, 1998 -----END PRIVACY-ENHANCED MESSAGE-----